Drug Profile
AVE 1231
Latest Information Update: 17 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atrial fibrillation
Most Recent Events
- 05 Sep 2007 Data presented at the European Society of Cardiology Congress 2007 (ESC-2007) added to the Arrhythmias pharmacodynamics section
- 07 Oct 2005 Phase-I clinical trials in Atrial fibrillation in Europe (unspecified route)
- 19 Apr 2005 Preclinical trials in Atrial fibrillation in Europe (unspecified route)